COVID-19-associated Invasive Pulmonary Mucormycosis:A Case Report and Literature Review
10.13241/j.cnki.pmb.2025.13.017
- VernacularTitle:COVID-19合并侵袭性肺毛霉菌病感染病例报道与文献综述
- Author:
Bing-qian YI
1
;
Bo-wen XU
1
;
Xi YU
1
;
Huan-huan BI
1
;
Yu-ting XIAO
1
;
Hong-mei WANG
1
;
Ning CUI
1
;
Jia-xing SUN
1
Author Information
1. 青岛大学附属医院呼吸与危重症医学科 山东青岛 266003
- Publication Type:Journal Article
- Keywords:
COVID-19;
Invasive pulmonary mucormycosis;
Diabetic ketosis;
Amphotericin B liposome;
Bronchoscopic treatment;
Metagenomic Sequencing
- From:
Progress in Modern Biomedicine
2025;25(13):2216-2222
- CountryChina
- Language:Chinese
-
Abstract:
Objective:Invasive pulmonary mucormycosis(PM)is a rare but highly lethal opportunistic infection.COVID-19 associated mucormycosis(CAM)is difficult to diagnose,often leading to misdiagnosis or missed diagnosis,and has poor treatment outcomes.This study reports a case of successfully treated CAM and explores optimized diagnostic and therapeutic strategies.Methods:A retrospective analysis of the diagnosis and treatment process in a 50-year-old female patient with COVID-19 associated with diabetic ketoacidosis(DKA)and invasive pulmonary mucormycosis was conducted.Combined with a literature review,the therapeutic efficacy of local bronchoscopic instillation in conjunction with systemic treatment using liposomal Amphotericin B(L-AmB)was specifically evaluated.Results:The patient was rapidly diagnosed with Rhizopus microsporus infection through metagenomic next-generation sequencing(mNGS).She subsequently received antifungal treatment with intravenous L-AmB combined with local bronchoscopic instillation.After treatment,the patient was significantly improved,with imaging studies showing gradual absorption of the lesions.Follow-up at six months revealed no recurrence.A literature review suggests that early diagnosis and multimodal therapy are key to improving survival rates in patients with CAM.Conclusion:mNGS can significantly improve the early diagnosis rate of CAM.The combination of local and systemic treatment with L-AmB is valuable in improving prognosis.Early diagnosis,multimodal antifungal therapy,and individualized management are key to increasing the survival rate of patients with CAM.
